Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]
In development
Reference number: GID-TA10620
Expected publication date:
Please note that following on from information received from the company the timelines have been revised to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2025.